CohBar Stock Doubles: Company Agrees To Merge With Morphogenesis To Advance Late-Stage Oncology Candidates
Portfolio Pulse from Vandana Singh
CohBar Inc (NASDAQ:CWBR) has agreed to merge with privately-held Morphogenesis Inc in an all-stock transaction to form a company focusing on late-stage oncology pipeline. The combined company, TuHURA Biosciences Inc, is expected to trade on The Nasdaq Capital Market and close the transaction in Q3 2023.
May 23, 2023 | 4:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CohBar's stock price doubled after announcing a merger with Morphogenesis to form TuHURA Biosciences Inc, focusing on late-stage oncology pipeline. The transaction is expected to close in Q3 2023.
The merger announcement between CohBar and Morphogenesis has led to a significant increase in CohBar's stock price, as the combined company will focus on advancing late-stage oncology candidates. This news is highly relevant and important for investors in CWBR, as it indicates a strategic move to strengthen their position in the oncology market. The stock price has already doubled, showing a positive short-term impact.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100